Trials / Completed
CompletedNCT00179686
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles. Subjects will continue until disease progression is documented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 |
Timeline
- Start date
- 2005-03-01
- Completion
- 2006-07-01
- First posted
- 2005-09-16
- Last updated
- 2006-12-20
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00179686. Inclusion in this directory is not an endorsement.